Although the use of vasodilator therapy in sepsis is debated (6, 32, 33), a reduction of circulating ET-1 levels through a combined ETA/ETB receptor-targeted treatment regimen has been demonstrated to ameliorate microcirculatory deficit in sepsis (17). This evidence concerns the gene EDN1 and Sepsis.